All Updates

All Updates

icon
Filter
Funding
Exsilio Therapeutics emerges from stealth with USD 82 million Series A funding
Cell & Gene Therapy
Jun 25, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Jun 25, 2024

Exsilio Therapeutics emerges from stealth with USD 82 million Series A funding

Funding

  • Exsilio Therapeutics, a biotechnology company developing genomic medicines, emerged from stealth raising USD 82 million in a Series A funding round co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, CRISPR Therapeutics, and others.

  • The funding will advance Exsilio's platform for developing genomic medicines based on naturally occurring genetic elements that can be delivered via mRNA and lipid nanoparticles to insert therapeutic genes into the human genome. 

  • Exsilio is developing a new class of genomic medicines that leverages mRNA technology to deliver genes that can permanently integrate into cells, offering the possibility of curative effects. The company's platform combines predictive modeling and experimentation to engineer genetic elements for precise gene insertion into safe harbor sites in the genome. The approach aims to enable redosable and titratable genomic medicines for genetic diseases, cancer, and autoimmune conditions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.